{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T15:56:35Z","timestamp":1778082995352,"version":"3.51.4"},"reference-count":25,"publisher":"Japan Endocrine Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1507\/endocrj.ej23-0648","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T22:14:47Z","timestamp":1713996887000},"page":"603-616","source":"Crossref","is-referenced-by-count":14,"title":["Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study)"],"prefix":"10.1507","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9509-7170","authenticated-orcid":false,"given":"Sho","family":"Furusawa","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0713-221X","authenticated-orcid":false,"given":"Hiroshi","family":"Nomoto","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiho","family":"Oba-Yamamoto","sequence":"additional","affiliation":[{"name":"Sapporo Diabetes and Thyroid Clinic, Sapporo 060-0807, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Sapporo Diabetes and Thyroid Clinic, Sapporo 060-0807, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miki","family":"Ito","sequence":"additional","affiliation":[{"name":"Kurihara Clinic, Sapporo 004-0053, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyoshi","family":"Kurihara","sequence":"additional","affiliation":[{"name":"Kurihara Clinic, Sapporo 004-0053, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Aoki","sequence":"additional","affiliation":[{"name":"Aoki Clinic, Sapporo 003-0023, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aika","family":"Miya","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiraku","family":"Kameda","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinobu","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Atsumi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Davis TM, Chubb SA, Bruce DG, Davis WA (2016) Metabolic memory and all-cause death in community-based patients with type 2 diabetes: the fremantle diabetes study. Diabetes Obes Metab 18: 598\u2013606.","DOI":"10.1111\/dom.12655"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Rubin RR, Peyrot M (1999) Quality of life and diabetes. Diabetes Metab Res Rev 15: 205\u2013218.","DOI":"10.1002\/(SICI)1520-7560(199905\/06)15:3<205::AID-DMRR29>3.0.CO;2-O"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Ueki K, Sasako T, Okazaki Y, Kato M, Okahata S, et al. (2017) Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol 5: 951\u2013964.","DOI":"10.1016\/S2213-8587(17)30327-3"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Gaede P, Lund-Andersen H, Parving HH, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358: 580\u2013591.","DOI":"10.1056\/NEJMoa0706245"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, et al. (2022) Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 45: 2753\u20132786.","DOI":"10.2337\/dci22-0034"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Bouchi R, Kondo T, Ohta Y, Goto A, Tanaka D, et al. (2022) A consensus statement from the Japan Diabetes Society (JDS): a proposed algorithm for pharmacotherapy in people with type 2 diabetes. Diabetol Int 14: 1\u201314.","DOI":"10.1007\/s13340-022-00605-x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Seino Y, Yabe D (2013) Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: incretin actions beyond the pancreas. J Diabetes Investig 4: 108\u2013130.","DOI":"10.1111\/jdi.12065"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Tsapas A, Avgerinos I, Karagiannis T, Malandris K, Manolopoulos A, et al. (2020) Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis. Ann Intern Med 173: 278\u2013286.","DOI":"10.7326\/M20-0864"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Madsbad S (2016) Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab 18: 317\u2013332.","DOI":"10.1111\/dom.12596"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10 Nauck MA, Kemmeries G, Holst JJ, Meier JJ (2011) Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes 60: 1561\u20131565.","DOI":"10.2337\/db10-0474"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, et al. (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375: 311\u2013322.","DOI":"10.1056\/NEJMoa1603827"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, et al. (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375: 1834\u20131844.","DOI":"10.1056\/NEJMoa1607141"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13 Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, et al. (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394: 121\u2013130.","DOI":"10.1016\/S0140-6736(19)31149-3"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14 Pratley R, Amod A, Hoff ST, Kadowaki T, Lingvay I, et al. (2019) Oral semaglutide <i>versus<\/i> subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet 394: 39\u201350.","DOI":"10.1016\/S0140-6736(19)31271-1"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Yabe D, Nakamura J, Kaneto H, Deenadayalan S, Navarria A, et al. (2020) Safety and efficacy of oral semaglutide <i>versus<\/i> dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial. Lancet Diabetes Endocrinol 8: 392\u2013406.","DOI":"10.1016\/S2213-8587(20)30074-7"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16 Rosenstock J, Allison D, Birkenfeld AL, Blicher TM, Deenadayalan S, et al. (2019) Effect of additional oral semaglutide <i>vs.<\/i> sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA 321: 1466\u20131480.","DOI":"10.1001\/jama.2019.2942"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Li A, Su X, Hu S, Wang Y (2023) Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin Pract 198: 110605.","DOI":"10.1016\/j.diabres.2023.110605"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Overgaard RV, Hertz CL, Ingwersen SH, Navarria A, Drucker DJ (2021) Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes. Cell Rep Med 2: 100387.","DOI":"10.1016\/j.xcrm.2021.100387"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Ronn J, Jensen EP, Wewer Albrechtsen NJ, Holst JJ, Sorensen CM (2017) Glucagon-like peptide-1 acutely affects renal blood flow and urinary flow rate in spontaneously hypertensive rats despite significantly reduced renal expression of GLP-1 receptors. Physiol Rep 5: e13503.","DOI":"10.14814\/phy2.13503"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Fujita H, Morii T, Fujishima H, Sato T, Shimizu T, et al. (2014) The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential. Kidney Int 85: 579\u2013589.","DOI":"10.1038\/ki.2013.427"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Skov J, Pedersen M, Holst JJ, Madsen B, Goetze JP, et al. (2016) Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial. Diabetes Obes Metab 18: 581\u2013589.","DOI":"10.1111\/dom.12651"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Thomas MC (2017) The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes. Diabetes Metab 43 Suppl 1: 2S20\u20132S27.","DOI":"10.1016\/S1262-3636(17)30069-1"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23 Bunck MC, Diamant M, Eliasson B, Corn\u00e9r A, Shaginian RM, et al. (2010) Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care 33: 1734\u20131737.","DOI":"10.2337\/dc09-2361"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Astrup A, Carraro R, Finer N, Harper A, Kunesova M, et al. (2012) Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 36: 843\u2013854.","DOI":"10.1038\/ijo.2011.158"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Tonneijck L, Muskiet MH, Smits MM, van Bommel EJ, Heerspink HJ, et al. (2017) Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. J Am Soc Nephrol 28: 1023\u20131039.","DOI":"10.1681\/ASN.2016060666"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/71\/6\/71_EJ23-0648\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T04:29:57Z","timestamp":1719030597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/71\/6\/71_EJ23-0648\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej23-0648","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"EJ23-0648"}}